Thomas Hope, Professor in Residence at University of California, shared on LinkedIn:
“Can immunotherapy improve PRRT in high-grade NETs? Nicholas Fidelman led our pilot study combining pembrolizumab with 177Lu-DOTATATE, which is published in Clinical Cancer Research. Responses to PRRT in well-differentiated NETs with Ki-67 above 10% often don’t last, and checkpoint inhibitors have minimal single agent activity. We aimed to show that PRRT would prime an immune response.
In 26 patients, most with grade 3 NET, we saw a 35% response rate, median PFS of 13.3 months and median OS of 24.1 months. Responders had more proliferating CD8+ T cells and fewer myeloid-derived suppressor cells in their blood at baseline, indicating the importance of the immune system. It is unclear whether pembrolizumab adds benefit and randomized data will be needed to answer that.
Congratulations to Nicholas Fidelman for leading this study, and thanks to Emily bergsland, Lawrence Fong and the whole team, and to our patients.”
Title: Pembrolizumab and Peptide Receptor Radionuclide Therapy for Patients with Metastatic Well-Differentiated Neuroendocrine Tumors
Authors: Nicholas Fidelman, Kira Chan, Bridget P. Keenan, David Y. Oh, Kiersten Tucker, Arun Chumber, Ciara Benson, Alexander Cheung, Li Zhang, Emily K. Bergsland, Lawrence Fong, Thomas A. Hope
Key takeaways
- Study aim: The researchers explored whether adding pembrolizumab to PRRT could improve treatment responses in patients with metastatic, well-differentiated NETs.
- Participants: The study included 26 patients, most of whom had grade 3 tumors.
- Treatment results: The combination achieved a 35% response rate, with a median progression-free survival of 13.3 months and median overall survival of 24.1 months.
- Immune findings: Patients who responded had higher levels of proliferating CD8+ T cells and fewer myeloid-derived suppressor cells before treatment.
- Safety: Severe adverse events were reported in 54% of patients.
- Limitations: It is still unclear whether pembrolizumab provides additional benefits over PRRT alone. Further randomized studies are needed.
Overall: The results suggest that combining pembrolizumab with PRRT may be a promising approach for high-risk NETs, although its added benefit and safety need further investigation.
Read the full article.
You may also be interested in: